AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 116 filers reported holding AUDENTES THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 1.14 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $418,000 | -97.5% | 6,977 | -98.8% | 0.00% | -100.0% |
| Q3 2019 | $16,416,000 | -29.5% | 584,393 | -5.0% | 0.02% | -26.1% |
| Q2 2019 | $23,298,000 | -55.7% | 615,378 | -54.3% | 0.02% | -55.8% |
| Q1 2019 | $52,559,000 | +140.6% | 1,346,970 | +31.5% | 0.05% | +116.7% |
| Q4 2018 | $21,846,000 | -46.4% | 1,024,691 | -0.4% | 0.02% | -36.8% |
| Q3 2018 | $40,725,000 | +4.4% | 1,028,668 | +0.8% | 0.04% | 0.0% |
| Q2 2018 | $38,995,000 | +29.4% | 1,020,556 | +1.8% | 0.04% | +26.7% |
| Q1 2018 | $30,131,000 | +12.9% | 1,002,679 | +17.4% | 0.03% | +15.4% |
| Q4 2017 | $26,682,000 | +12.9% | 853,822 | +1.2% | 0.03% | +8.3% |
| Q3 2017 | $23,642,000 | +46.0% | 844,060 | -0.3% | 0.02% | +41.2% |
| Q2 2017 | $16,189,000 | +217.1% | 846,273 | +182.4% | 0.02% | +240.0% |
| Q1 2017 | $5,106,000 | -6.7% | 299,656 | 0.0% | 0.01% | -16.7% |
| Q4 2016 | $5,475,000 | +3.0% | 299,656 | +0.4% | 0.01% | 0.0% |
| Q3 2016 | $5,318,000 | – | 298,586 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 1,204,615 | $36,198,681,000 | 11.58% |
| Sofinnova Investments, Inc. | 1,380,303 | $41,478,000 | 7.13% |
| Casdin Capital, LLC | 450,000 | $13,523,000 | 2.38% |
| Foresite Capital Management III, LLC | 315,331 | $9,476,000 | 2.06% |
| Opaleye Management Inc. | 190,000 | $5,709,000 | 1.63% |
| Redmile Group, LLC | 1,308,526 | $39,321,000 | 1.52% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,384,470 | $41,603,000 | 1.44% |
| Orbimed Advisors | 3,522,100 | $105,839,000 | 1.31% |
| Rock Springs Capital Management LP | 565,000 | $16,978,000 | 0.72% |
| Cormorant Asset Management, LP | 322,945 | $9,704,000 | 0.72% |